Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Amaury Daste, Medical Oncologist, Hospital Center University de Bordeaux, France, and study investigator

“For patients with recurrent or metastatic head and neck squamous cell carcinoma, there is an ongoing need for new treatment approaches that may help expand options beyond currently available regimens.”

Amaury Daste, Medical Oncologist, Hospital Center University de Bordeaux, France, and study investigator

“The median overall survival of 28 months observed with petosemtamab plus pembrolizumab in this trial, along with a manageable safety profile, are impressive.”

Amaury Daste, Medical Oncologist, Hospital Center University de Bordeaux, France, and study investigator

“It is also particularly noteworthy that responses were observed across patient subgroups and continued to be maintained at the time of analysis, an important consideration for patients facing a disease where durable disease control remains a critical treatment goal.”

Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab

“These findings strengthen our confidence in petosemtamab’s potential to make a meaningful difference in first-line head and neck cancer”

Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab

“Seeing responses across both HPV-positive and HPV-negative disease reinforces our ambition to reach a broad patient population and our commitment to advancing the petosemtamab clinical development program.”